NCT00692185View on ClinicalTrials.gov

Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Eating Disorders
Interventions
DRUG

Olanzapine

Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.

DRUG

Placebo

Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.

Trial Locations (1)

10032

Eating Disorders Clinic, New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT00692185 - Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa | Biotech Hunter | Biotech Hunter